Top

Diabetologia

Published in:

01-03-2006 | Short Communication

Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men

Authors: M. Ridderstråle, L. E. Johansson, L. Rastam, U. Lindblad

Published in: Diabetologia | Issue 3/2006

Abstract

Aims/hypothesis

The variant allele of the Gly482Ser polymorphism in peroxisome proliferator-activated receptor-γ co-activator-1α (PPARGC1A or PGC1α), a critical determinant of skeletal muscle metabolism, has been associated with obesity and type 2 diabetes. Previous studies indicate that these risks depend on sex and environmental triggers such as age. The aim of the present study was to investigate the possible interactions between genotype and age and physical activity on risk of obesity.

Methods

We genotyped PPARGC1A Gly482Ser, in a population-based study comprising 899 women and 902 men aged between 30 and 75 years in Vara, Sweden.

Results

Genotyping revealed that 56% of the males and 57% of the females carried the PPARGC1A 482Ser variant allele. Elderly males (≥50 years) carrying 482Ser had an increased risk of obesity compared with subjects who were homozygous for the wild-type allele (odds ratio [OR]=1.99, 95% CI 1.14–3.47, p=0.015). The risk was restricted to males with a low leisure-time physical activity level, and was significantly weaker (OR=0.44, 95% CI 0.22–0.87, p=0.018) for the homozygous 482Gly carriers among this subgroup. No association with obesity was found in elderly males with a high level of physical activity, in younger males, or in females of any age group or level of physical activity.

Conclusions/interpretation

Our findings confirm that sex and age should be considered when investigating the influence of the PPARGC1A Gly482Ser polymorphism on metabolic disease. The risk of obesity associated with 482Ser is evident only in physically inactive elderly male subjects. Whenever possible, the level of physical activity should be addressed in future studies on disease risk associated with PPARGC1A Gly482Ser.

McCarty MF (2005) Up-regulation of PPARγ coactivator-1α as strategy for preventing and revering insulin resistance and obesity. Med Hypotheses 64:399–407CrossRefPubMed

Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273CrossRefPubMed

Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100:8466–8471CrossRefPubMed

Stone S, Abkevich V, Hunt SC et al (2002) A major predisposition locus for severe obesity, at 4p15–p14. Am J Hum Genet 70:1459–1468CrossRefPubMed

Ek J, Andersen G, Urhammer SA et al (2001) Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 44:2220–2226CrossRefPubMed

Hara K, Tobe K, Okada T et al (2002) A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia 45:740–743CrossRefPubMed

Esterbauer H, Oberkofler H, Linnemayer V et al (2002) Peroxisome proliferator-activated receptor-γ coactivator-1 gene locus. Association with obesity indices in middle-aged women. Diabetes 51:1281–1286PubMedCrossRef

Ling C, Poulsen P, Carlsson E et al (2004) Multiple environmental and genetic factors influence skeletal muscle PGC-1α and PGC-1β gene expression in twins. J Clin Invest 114:1518–1526CrossRefPubMed

Bøg-Hansen E, Merlo J, Gullberg B, Melander A, Rastam L, Lindblad U (2004) Survival in patients with hypertension treated in primary care. A population-based follow-up study in the Skaraborg Hypertension and Diabetes Project. Scand J Prim Health Care 22:222–227CrossRefPubMed

10.

Caspersen CJ, Powell KE, Christenson GM (1985) Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 100:126–131PubMed

11.

Ambye L, Rasmussen S, Fenger M et al (2005) Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor g coactivator 1α (PGC-1α) gene in Danish subjects with the metabolic syndrome. Diabetes Res Clin Pract 67:175–179CrossRefPubMed

12.

Lacquemant C, Chikri M, Boutin P, Samson C, Frougel P (2002) No association between the G482S polymorphism of the proliferator-activated receptor-γ coactivator-1 (PGC-1) gene and type II diabetes in French Caucasians. Diabetologia 45:602–603CrossRefPubMed

13.

Andruliontytè L, Zacharova J, Chiasson J-L, Laakso M (2004) Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47:2176–2184CrossRefPubMed

14.

Lin J, Wu H, Tarr PT et al (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418:797–801CrossRefPubMed

15.

Nyholm B, Qu Z, Kaal A et al (1997) Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes 46:1822–1828PubMedCrossRef

Title: Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men
Authors: M. Ridderstråle
L. E. Johansson
L. Rastam
U. Lindblad
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 3/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-005-0129-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 3/2006

How to screen for depression and emotional problems in patients with diabetes: comparison of screening characteristics of depression questionnaires, measurement of diabetes-specific emotional problems and standard clinical assessment

Preterm birth and later insulin resistance: effects of birth weight and postnatal growth in a population based longitudinal study from birth into adult life

Comment to: Patti ME, Mcmahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240

Major quantitative trait locus on chromosome 2 for glucose tolerance in diabetic SMXA-5 mouse established from non-diabetic SM/J and A/J strains

In treatment-naïve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100

Evidence that oestrogen receptor-α plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials